Accelerated Increase in Serum Interleukin-1 Receptor Antagonist Starts 6 Years Before Diagnosis of Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Although interleukin-1 receptor antagonist (IL-1Ra) treatment is associated with improved β-cell function and glycemic control in patients with type 2 diabetes, its role in the development of type 2 diabetes remains unclear. We used repeated measurements to characterize IL-1Ra trajectories in individuals who developed type 2 diabetes. RESEARCH DESIGN AND METHODS: This case-cohort study, nested within the Whitehall II cohort, was based on 335 incident type 2 diabetes cases and 2,475 noncases. We measured serum IL-1Ra levels at up to three time points per individual and estimated retrospective trajectories of IL-1Ra before diabetes diagnosis (case subjects) or end of follow-up (control subjects) using multilevel analysis. Models were adjusted for age, sex, and ethnicity. RESULTS: IL-1Ra levels were already higher in the case than control subjects 13 years before diabetes diagnosis/end of follow-up (mean [95% CI] 302 [290–314] vs. 244 [238–249] pg/ml). In control subjects, IL-1Ra levels showed a modest linear increase throughout the study period. In case subjects, IL-1Ra trajectories were parallel to those in control subjects until 6 years (95% CI 7.5–4.5) before diagnosis and then rose steeply to 399 (379–420) pg/ml at the time of diagnosis (P < 0.0001 for slope difference). Adjustment for BMI and waist circumference as time-varying covariates had little impact on these trajectories. CONCLUSIONS: We show elevated IL-1Ra levels for 13 years and an accelerated increase during the last 6 years before type 2 diabetes diagnosis, indicating the presence of an anti-inflammatory response that may act to counterbalance the metabolic and immunologic disturbances that precede type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most recent attempts to improve diabetes prediction using measurements from genetics and transcriptomics have not shown significant improvements in predictive performance but it is unknown whether serial measurements may decrease variations in non-genetic biomarkers allowing for a more precise estimation of their levels.34–36”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence
Singer, J. D., & Willett, J. B. (2003) · doi:10.1093/acprof:oso/9780195152968.001.0001 · Cited by 10,647
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes
Spranger, J., Kroke, A., Möhlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M., Boeing, H., & Pfeiffer, A. F. H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.812 · Cited by 1,493 · cited 1×
“However, it has been suggested that elevation of only IL-1 may not be sufficient to increase risk of type 2 diabetes; instead, increased IL-1 in combination with elevated levels of other proinflammatory cytokines may be required (28), thus limiting the predictive relevance of the IL-1Ra/IL-1 ratio without consideratio…”
BackgroundRelationship between Adipocyte Size and Adipokine Expression and Secretion
Skurk, T., Alberti-Huber, C., Herder, C., & Hauner, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1055 · Cited by 1,288 · cited 1×
“The finding that the difference in trajectories between case and control subjects could not be explained by obesity is important because adipose tissue is a major producer of IL-1Ra (9,29).”
BackgroundSelf-citationInsulin sensitivity: Modulation by nutrients and inflammation
Schenk, S., Saberi, M., & Olefsky, J. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34260 · Cited by 1,191
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Cited by
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
“, with an accelerated increase in IL-1RA levels before the onset of T2”
BackgroundPrediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
Self-citationAnti-inflammatory effects of exercise: role in diabetes and cardiovascular disease
Pedersen, B. K. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12781 · Cited by 617
Bjermo, H., Iggman, D., Kullberg, J., Dahlman, I., Johansson, L., Persson, L., Berglund, J., Pulkki, K., Basu, S., Uusitupa, M., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.030114 · Cited by 490
A review of the evidence for pathogenic mechanisms that may link periodontitis and diabetes
Taylor, J. J., Preshaw, P. M., & Lalla, E. (2013) · Journal of Clinical Periodontology · doi:10.1111/jcpe.12059 · Cited by 425
“A number of clinical trials provide evidence for the utility of cytokine analysis in pre-clinical diagnosis of T2DM (Carstensen et al. 2010) and for cytokine blockade in therapy for T2DM (Larsen et al.”
Background
Metadata
- Authors
- Carstensen, M., Herder, C., Kivimäki, M., Jokela, M., Roden, M., Shipley, M. J., Witte, D. R., Brunner, E. J., & Tabák, A. G.
- Affiliations
- Deutsches Diabetes-Zentrum e.V. (DE)
- Department of Epidemiology and Public Health, University College London, London, U.K.;
- University College London (GB)
- Düsseldorf University Hospital (DE)
- Corresponding author
- Herder, Christian
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-02-25
- Volume
- 59
- Issue
- 5
- Pages
- 1222-1227
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2857902
- OpenAlex
- W2126985857
- Cited by
- 137
- References
- 38
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 8 · 2021: 9 · 2020: 3 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 11 · 2015: 10 · 2014: 16 · 2013: 16 · 2012: 10
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- John D. and Catherine T. MacArthur Foundation
- British Heart Foundation (RG/07/008/23674)
- Bupa Foundation
- Health and Safety Executive
- Academy of Finland
- Bundesministerium für Gesundheit
- Novo Nordisk
- National Institutes of Health
- Agency for Healthcare Research and Quality (HS06516)
- Medical Research Council
- Economic and Social Research Council
- National Institute on Aging (AG 13196, R37AG013196, R01AG013196)
- National Heart, Lung, and Blood Institute (R01HL036310)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- interleukin-1 receptor antagonist, type 2 diabetes, prediabetes, serum biomarkers, biomarker trajectories, anti-inflammatory response, inflammation, beta-cell function, Whitehall II cohort
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Cohort Studies, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Accelerated Increase in Serum Interleukin-1 Receptor Antagonist Starts 6 Years Before Diagnosis of Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/db09-1199
- The paper
- Carstensen, M., Herder, C., Kivimäki, M., Jokela, M., Roden, M., Shipley, M. J., Witte, D. R., Brunner, E. J., & Tabák, A. G. (2010). Accelerated Increase in Serum Interleukin-1 Receptor Antagonist Starts 6 Years Before Diagnosis of Type 2 Diabetes. Diabetes. https://doi.org/10.2337/db09-1199
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.